.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BB06_Clofarabine.Clofarabine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BB06_Clofarabine.Clofarabine| name: | Clofarabine |
| ATC code: | L01BB06 | route: | intravenous |
| n-compartments | 2 |
Clofarabine is a purine nucleoside antimetabolite used primarily in the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients. It is also used off-label for other hematologic malignancies. Clofarabine is approved for use in several countries for specific indications.
Pharmacokinetic parameters derived from pediatric patients (ages 1–21 years) with relapsed or refractory ALL after intravenous infusion.
Bonate, PL, et al., & Weitman, S (2011). Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer chemotherapy and pharmacology 67(4) 875–890. DOI:10.1007/s00280-010-1376-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/20582417
Suzuki, T, et al., & Ogura, M (2013). Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan. Japanese journal of clinical oncology 43(12) 1177–1183. DOI:10.1093/jjco/hyt155 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24130086
Andersson, BS, et al., & Champlin, RE (2011). Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 17(6) 893–900. DOI:10.1016/j.bbmt.2010.09.022 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20946966